Researchers at The Feinstein Institutes for Medical Research have shown that electrically stimulating the vagus nerve can reduce bleeding in preclinical hemophilic mice models a finding that could translate into human patients, Feinstein Institute officials said.
The study, published in Nature Communications, builds on years of research into harnessing the vagus nerve through electrical stimulation, a foundation of bioelectronic medicine.
Led by Jared Huston, MD, associate professor of surgery and science education at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Institute of Bioelectronic Medicine at the Feinstein Institutes, the research shows that vagus nerve stimulation reduces bleeding in hemophilia A mice to the same degree as replacing missing clotting factor the current gold-standard therapy for patients living with hemophilia.
Dr. Huston and team have dubbed the effects a "neural tourniquet" to help curb excessive bleeding.
The vagus nerve runs from the brain to the periphery and communicates with all major organs.
It helps control essential functions, like heart rate and breathing, and is the main conduit for the body's inflammatory immune response to disease, bacteria and viruses.
By stimulating the nerve with electrical impulses, you can control inflammation and organ function.
Dr. Huston's research shows that the vagus nerve targets the spleen, which stores one-third of our platelets, the primary cell that controls bleeding throughout the body.
The paper shows that after stimulation primed platelets travel in the bloodstream to sites of injury where they trigger more effective blood clotting, in some circumstances decreasing traumatic blood loss by 75%.
As part of Dr. Huston's research program investigating vagus nerve stimulation in post-traumatic hemorrhage, he was also a winner of Northwell Health's 2021 Innovation Challenge.
The challenge awards four employees from the health system funding that totals USD 1.3m towards their driven projects that have the potential to transform the future of medicine.
The Feinstein Institutes is known as the global scientific home of bioelectronic medicine because of early discoveries in its labs.
Decades ago, Dr. Tracey and his colleagues identified the role the vagus nerve plays in controlling our body's immune response, defining it as the inflammatory reflex.
Researchers continue to build off that work worldwide to develop devices to cure disease.
Built on years of research in molecular mechanisms of disease and the link between the nervous and immune systems, our researchers have uncovered neural targets that can be activated or inhibited with neuromodulation devices like vagus nerve implants to regulate the body's immune response and inflammation.
If inflammation is successfully controlled, diseases such as arthritis, pulmonary hypertension, Crohn's disease, inflammatory bowel diseases, diabetes, cancer and autoimmune diseases can be treated more effectively.
By producing bioelectronic medicine knowledge, disease and injury could one day be treated with our own nerves without costly and potentially harmful pharmaceuticals.
The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State.
The Feinstein Institutes encompasses 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA